Neo Cremar Co., Ltd. · 韩国DNF-10® 低分子酵母肽DNF-10® low-molecular-weight yeast peptide
韩国 Neo Cremar 出品的酵母水解物，肽段分子量小于 10 kDa，美国 FDA GRAS 通知在案。
A yeast hydrolysate from Neo Cremar, Korea: peptides below 10 kDa, with a US FDA GRAS notification on file.
酿酒酵母水解物（含麦芽糊精载体）Saccharomyces cerevisiae hydrolysate with maltodextrin carrier
- 生物来源 Source
- 酿酒酵母 Saccharomyces cerevisiae
- 形态 Form
- 浅黄至棕色粉末，30–40 目
- 蛋白 Protein
- ≥ 40%（批次典型值约 56%）
- 分子量 MW
- 肽段平均 ≤ 10 kDa（超滤分级）
- 载体 Carrier
- 麦芽糊精约 20%，喷雾干燥
- 水分 Moisture
- ≤ 8%
- 保质期 Shelf life
- 36 个月，室温避光防潮
- 法规身份 Status
- 美国 FDA GRAS 通知；韩国食品原料；中国准入路径以单品资料为准
FDA GRASNon-GMO 声明无溶剂工艺声明韩国 · 欧盟 · 德国专利
它是什么What it is
DNF-10 是酿酒酵母经蛋白酶水解、固液分离和小分子膜分级后得到的可溶性混合物，以麦芽糊精为载体喷雾干燥成粉。它不是单一纯化肽，而是由游离氨基酸、短肽、糖类和酵母矿物质组成的复合原料，质量以组成分布和指纹图谱定义。
DNF-10 is the soluble fraction of brewer's yeast after enzymatic hydrolysis, solid–liquid separation and low-molecular-weight membrane fractionation, spray-dried on a maltodextrin carrier. It is a defined mixture of free amino acids, short peptides, carbohydrates and yeast minerals rather than a single purified peptide, so quality is specified by composition and fingerprint.
- 酵母原料Yeast raw material
- 蛋白酶水解Protease hydrolysis
- 压滤 / 固液分离Filtration / solid–liquid separation
- 超滤，目标 < 10 kDaUltrafiltration, target < 10 kDa
- 0.2 μm 微滤 · 蒸发浓缩0.2 μm microfiltration · evaporation
- 90 °C 热杀菌Heat sterilisation at 90 °C
- 加麦芽糊精 · 喷雾干燥Maltodextrin added · spray drying
- 筛分 · 磁选 · 包装Sieving · magnetic separation · packing
组成与规格Composition & specification
FDA GRAS 通知的 4 批分析平均值：游离氨基酸约 38%，3–7 肽约 8%，8–28 肽约 0.8%，未检出 29 肽以上组分；含谷氨酸、天冬氨酸、丙氨酸、赖氨酸、亮氨酸及 GABA。供应商营养成分表：蛋白 59.5 g/100 g、碳水 28.4 g、脂肪 2.9 g、灰分 4.8 g、钾 3.8 g。
Four-batch averages in the FDA GRAS notice: free amino acids about 38%, 3–7-residue peptides about 8%, 8–28-residue peptides about 0.8%, none above 29 residues; glutamic and aspartic acid, alanine, lysine, leucine and GABA are reported. Supplier nutrition data: protein 59.5 g/100 g, carbohydrate 28.4 g, fat 2.9 g, ash 4.8 g, potassium 3.8 g.
研究方向：能量摄入与体重管理Research area: energy intake and weight management
以下为已发表研究的设计与观察结果摘录，供研发与法规评估参考；不构成对原料或终端产品的功能宣称。
Design and reported observations of published studies, provided for R&D and regulatory review only. Not a functional claim for the ingredient or any finished product.
- 2011
随机对照，20 名女性，1 g/天，4 周
Randomised controlled, 20 women, 1 g/day, 4 weeks
报告组间体重差约 −0.97 kg，BMI 改善；体脂与围度多项未达显著。
Reported between-group weight difference of about −0.97 kg with BMI improvement; most fat-mass and circumference measures not significant.
- 2014
安慰剂对照，54 名完成者，1 g/天，10 周
Placebo-controlled, 54 completers, 1 g/day, 10 weeks
报告体重 −2.60 kg 对 +0.83 kg，脂肪量 −2.00 kg 对 +1.12 kg，腰围 −5.04 cm 对 +0.83 cm；后期记录能量摄入下降。
Reported body weight −2.60 kg vs +0.83 kg, fat mass −2.00 kg vs +1.12 kg, waist −5.04 cm vs +0.83 cm; lower energy intake recorded later in the study.
- 2017
对照试验，30 名肥胖女性，0.5 g/天，8 周
Controlled trial, 30 obese women, 0.5 g/day, 8 weeks
报告体重 −1.61 kg 对 +0.09 kg，脂肪量 −2.02 kg 对 −0.04 kg，并记录食欲与甜食偏好自评。
Reported body weight −1.61 kg vs +0.09 kg, fat mass −2.02 kg vs −0.04 kg, with self-rated appetite and sweet-food preference.
- 2025
系统综述与 Meta 分析，6 项酵母水解物 RCT，共 262 人
Systematic review and meta-analysis, 6 yeast-hydrolysate RCTs, 262 participants
汇总体重平均差约 −3.08 kg，BMI −0.87，脂肪量 −1.93 kg；腰围差异未达显著。作者将证据确定性评为低。
Pooled mean difference in body weight about −3.08 kg, BMI −0.87, fat mass −1.93 kg; waist not significant. Authors rated certainty of evidence as low.
安全性数据Safety data
人体研究周期 4–10 周，未报告治疗相关严重不良事件。2021 年大鼠试验：急性 5,000 mg/kg 与 90 天 1,000 mg/kg/天未见明显毒性。酵母来源，酵母或酶制剂过敏者、痛风及高尿酸人群、孕哺期与儿童缺乏直接数据，配方设计时应予提示。
Human studies ran 4–10 weeks with no treatment-related serious adverse events reported. A 2021 rat study found no overt toxicity at 5,000 mg/kg acute and 1,000 mg/kg/day for 90 days. As a yeast-derived material, note yeast or enzyme allergy, gout and hyperuricaemia, and the absence of direct data in pregnancy, lactation and children when formulating.
应用Applications
固体饮料、代餐粉、压片糖果、胶囊、功能性饮料。人体研究用量 0.5–1 g/天。模型体系中小分子组分在 140–160 °C、30 分钟条件下较稳定；实际配方仍需做杀菌与货架期验证。
Powdered beverages, meal-replacement powders, pressed tablets, capsules and functional drinks. Doses used in human studies: 0.5–1 g/day. Low-molecular-weight fractions were stable at 140–160 °C for 30 minutes in model systems; sterilisation and shelf-life must still be validated in the final formula.
专利与商标Patents & trademarks
- KR 10-0999429酵母水解物及其制法韩国，有效至 2030-04
- KR 10-1372526含酵母水解物的组合物（与高丽大学共有）韩国，有效至 2032-05
- EP 2564860 B1欧洲专利，德国生效有效至 2031-04
- DNF-10®Neo Cremar 注册商标韩国、欧盟、美国、中国等
资料Documents
标注「申请获取」的资料受供应商约定限制，提交索样 / 询价表单并注明所需文件，我们会在核实后发送。
Documents marked "on request" are subject to supplier agreements. Submit the request form, name the files you need, and we will send them after verification.
本页信息来自供应商文件与公开发表的研究，供研发与法规评估参考，不代表原料或终端产品在中国可直接宣称相应功能。
Information on this page comes from supplier documents and published research and is provided for R&D and regulatory review. It does not constitute or permit any health-function claim for the ingredient or finished products sold within China.